Enhanced immune recognition of cryptic glycan markers in human tumors

Cancer Research

Volumn 69, Issue 5, 2009, Pages 2018-2025

  Newsom Davis, Thomas E ^a   Wang, Denong ^b   Steinman, Lawrence ^c   Chen, Paul F T ^a   Wang, Lai Xi ^d   Simon, A Katharina ^e   Screaton, Gavin R ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b STANFORD UNIVERSITY   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^e JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CARBOHYDRATE; CARBOHYDRATE ANTIGEN; EPITOPE; FAS ANTIBODY; FAS LIGAND; GLYCAN; IMMUNOGLOBULIN M ANTIBODY; MANNOSE; MEMBRANE PROTEIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY TM10; MONOCLONAL ANTIBODY TM12; MONOCLONAL ANTIBODY TM3; MONOCLONAL ANTIBODY TM5; MONOCLONAL ANTIBODY TM6; TUMOR ANTIGEN; UNCLASSIFIED DRUG; POLYSACCHARIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIGEN BINDING; ANTIGEN RECOGNITION; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER IMMUNIZATION; CONTROLLED STUDY; FEMALE; GLYCOSYLATION; HUMAN; HUMAN CELL; IMMUNOLOGICAL TOLERANCE; MELANOMA CELL; MOUSE; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; PROSTATE CANCER; TUMOR CELL; TUMOR IMMUNITY; TUMOR IMMUNOLOGY; ANIMAL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; BAGG ALBINO MOUSE; C3H MOUSE; C57BL MOUSE; DBA MOUSE; IMMUNOLOGY; NEOPLASM; TUMOR CELL LINE; VACCINATION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTIGENS, TUMOR-ASSOCIATED, CARBOHYDRATE; CELL LINE, TUMOR; EPITOPES; FAS LIGAND PROTEIN; GLYCOSYLATION; HUMANS; MANNOSE; MICE; MICE, INBRED BALB C; MICE, INBRED C3H; MICE, INBRED C57BL; MICE, INBRED DBA; NEOPLASMS; POLYSACCHARIDES; VACCINATION;

EID: 62449091054     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-08-3589     Document Type: Article

References (31)

1. Itoh N, Yònehara S, Ishii A, et al. The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell 1991:66:233-243
2. Suda T1 Takahashi T1 Golstein P1 Nagata S. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 1993; 75:11169-1178.
3. Peter ME, Budd RC, Desbarats J, et al. The CD95 receptor: apoptosis revisited. Cell 2007;129:447-450
4. Seino K, Kayagaki N, Okumura K, Yagita H. Antitumor effect of locally produced CD95 ligand. Nat Med. 1997 :3: 165-170
5. Shimizu M, Fontana A, Takeda Y, Yagita H, Yoshimoto T1 Matsuzawa A. Induction of antitumor immunity with Fas/APO-1. ligand (CD95L)-transfected neuroblastoma neuro-2a cells. J Immunol 1999:162: 7350-7357
6. Simon AK1 Gallimore A, Jones E, Sawitzki B, Cerundolo V, Screaton GR. Fas ligand breaks tolerance to self-antigens and induces tumor immunity mediated by antibodies. Cancer Cell 2002;2:315-322
7. Aarnoudse CA, Garcia Vallejo JJ, Saeland E, van Kooyk Y. Recognition of tumor glycans by antigen-presenting cells. Curr Opin Immunol 2006;18:105-111
8. Hakomori S. Aberrant glycosylation in tumors and tumor-associated carbohydrate antigens. Adv Cancer Res 1989;52:257-331.
9. Dube DH, Bertozzi CR. Glycans in cancer and inflammation-potential for therapeutics and diagnos-tics. Nat Rev Drug Discov 2005;4:477-488
10. Yòshimura M, Ihara Y1 Matsuzawa Y1 Taniguchi N. Aberrant glycosylation of E-cadherin enhances cell-cell binding to suppress metastasis. J Biol Chem 1996:271: 13811-13815
11. Reddy BV Kalraiya RD. Sialilated (U,6 branched N-oligosaccharides modulate adhesion, Chemotaxis and motility of melanoma cells: effect on invasion and spontaneous metastasis properties. Biochim Biophys Acta 2006:1760:1393-402.
12. Slovin SF, Keding SJ, Ragupathi G. Carbohydrate vaccines as immunotherapy for cancer. Immunol Cell Biol 2005;83:418-428
13. Wang R, LIu S, Shah D, Wang D. A practical protocol for carbohydrate microarrays. Methods MoI Biol 2005; 310:241-252
14. Bowie WB, Srinivasan. R, Wolchok JD, et al. Coupling and uncoupling of tumor immunity and autoimmunity. J Exp Med. 1999;190:1717-1722
15. Wang LX, Ni J, Singh S, Li H. Binding of high-mannose-type oligosaccharides and synthetic oligoman-nose clusters to human antibody 2G12: implications for HTV-I vaccine design. Chem Biol 2004:11:127-134
16. Ni J, Song H, Wang Y, Stamatos NM, Wang LX. Toward a carbohydrate-based HIV-I. vaccine: synthesis and immunological studies of oligomannose-contalning glycoconjugates. Bioconjug Chem 2006:17:493-500.
17. Kaku H, Peumans WJ, Goldstein IJ. Isolation and characterization of a second lectin (SNA-II) present in elderberry (Sambucus nigra L.) bark. Arch Biochem Biophys 1990;277:255-262
18. Ragupathi G. Carbohydrate antigens as targets for active specific immunotherapy. Cancer Immunol Immunother 1996;43:152-157
19. van Gisbergen KP, Aamoudse CA, Meijer GA, Geijtenbeek TB, van Kooyk. Y. Dendritic cells recognize tumor-specific glycosylation of carcinoembryonic anti-gen on colorectal cancer cells through dendritic cell-specific intercellular adhesion molecule-3-grahhing nonintegrin. Cancer Res 2005;65:5935-5944
20. Hodges A, Sharrocks K, Edelmann M, et al. Activation of the lectin DC-SIGN induces an immature dendritic cell phenotype triggering Rho-GTPase activity required for HIV-I. replication. Nat Immunol 2007;8:569-577
21. Simon AK, Newsom-Davis T, Frayne ME, Ch'en PF, McMichael AJ, Screaton GR. Generation of tumour-rejecting anti-carbohydrate monoclonal antibodies us-ing melanoma modified with Fas ligand. Int Immunol 2008;20:525-534
22. Zhang GX, Gran B, Yu S, et al. Induction of experimental autoimmune encephalomyelitis in IL-12 receptor-ß2-deficient mice: IL-12 responsiveness is not required in the pathogenesis of inflammatory demye-lination in the central nervous system. J Immunol 2003;. 170:2153-2160.
23. Liu T, Guo Z, Yang Q, Sad S, Jennings HJ. Biochemical engineering of surface a2-8 polysialic acid for immu-notargeting tumor cells. J Biol Chem 2000:275: 32832-32836
24. Scott AM, Liu Z1 Murone C1 et al. Immunological effects of chimeric anti-GD3 monoclonal antibody KM871 in patients with metastatic melanoma. Cancer Immun 2005:5:3.
25. Posey JA, Khazaeli MB, Bookman MA et al. A phase I trial of the single-chain immunotoxin SGN-.10 (BR96 S.FV-PE40) in patients with advanced solid tumors. Clin Cancer Res 2002;8:3092-3099
26. Saleh MN, Sugarman S, Murray J, et al. Phase I trial of the anti-Lewis Y drug immunoconjugate BR96-doxorubicin in patients with Lewis Y-expressing epithe-lial tumors. J Clin Oncol 2000:18:2282-2292
27. Livingston PO, Wong GY, Adluri S, et al. Improved survival in stage HI melanoma patients with G.M2 antibodies: a randomized trial, of adjuvant vaccination with GM2 ganglioside. J CUn Oncol 1994;12:1036-1044
28. Perez CA Ravindranath MH, Soh D, Gonzales A, Ye W, Morton DL. Serum anti-ganglioside IgM antibodies in soft tissue sarcoma: clinical prognostic implications. Cancer J 2002;8:384-394
29. Ravindranath MH, Muthugounder S, Presser N, Ye X, Brosman S, Morton DL. Endogenous immune response to gangliosides in patients with confined prostate cancer. Int J Cancer 2005:116:368-377
30. Adams GP, Weiner LM. Monoclonal antibody therapy of cancer. Nat Biotechnol 2005:23:1147-1157
31. Bajorin DF, Chapman PB1 Wong G1 et al. Phase I evaluation of a combination of monoclonal antibody R24 and interleukin 2 in patients with metastatic melanoma. Cancer Res 1990;50:7490-7495